GW&K Investment Management LLC Purchases 354,359 Shares of Agios Pharmaceuticals, Inc. $AGIO

GW&K Investment Management LLC lifted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 41.5% during the 4th quarter, Holdings Channel reports. The firm owned 1,207,301 shares of the biopharmaceutical company’s stock after acquiring an additional 354,359 shares during the period. GW&K Investment Management LLC’s holdings in Agios Pharmaceuticals were worth $32,863,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in AGIO. Assetmark Inc. grew its holdings in shares of Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter worth approximately $40,000. Eurizon Capital SGR S.p.A. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $72,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 588 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the third quarter worth approximately $79,000.

Agios Pharmaceuticals Trading Up 2.6%

Shares of AGIO opened at $28.88 on Thursday. The firm’s 50-day moving average price is $29.54 and its 200-day moving average price is $28.46. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -3.98 and a beta of 0.59. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business’s revenue was up 137.7% compared to the same quarter last year. On average, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.2 EPS for the current fiscal year.

Analysts Set New Price Targets

AGIO has been the subject of a number of recent analyst reports. HC Wainwright lowered their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Bank of America lowered their price target on Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, May 29th. Truist Financial lowered their price target on Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Citigroup upped their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Finally, The Goldman Sachs Group upped their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $41.44.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 2,940 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $102,047.40. Following the sale, the insider owned 80,277 shares of the company’s stock, valued at approximately $2,786,414.67. The trade was a 3.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the completion of the transaction, the chief financial officer owned 54,998 shares of the company’s stock, valued at approximately $1,908,980.58. This trade represents a 5.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 12,623 shares of company stock worth $438,144. 5.40% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.